Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.

Iwadate Y, Matsutani T, Hara A, Hirono S, Ikegami S, Kobayashi M, Ito D, Kawauchi D, Horiguchi K, Tamiya A, Higuchi Y.

J Neurooncol. 2019 Jan;141(1):205-211. doi: 10.1007/s11060-018-03027-5. Epub 2018 Dec 18.

PMID:
30565028
2.

Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.

Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Higuchi Y, Saeki N.

J Neurooncol. 2011 May;102(3):443-9. doi: 10.1007/s11060-010-0340-4. Epub 2010 Aug 19.

PMID:
20721680
3.

Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.

McNamara MG, Jiang H, Lim-Fat MJ, Sahebjam S, Kiehl TR, Karamchandani J, Coire C, Chung C, Millar BA, Laperriere N, Mason WP.

Can J Neurol Sci. 2017 May;44(3):288-294. doi: 10.1017/cjn.2016.420.

PMID:
28488951
4.

Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.

Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K.

Brain Pathol. 2008 Jul;18(3):360-9. doi: 10.1111/j.1750-3639.2008.00129.x. Epub 2008 Mar 26.

PMID:
18371182
5.

Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.

Taal W, van der Rijt CC, Dinjens WN, Sillevis Smitt PA, Wertenbroek AA, Bromberg JE, van Heuvel I, Kros JM, van den Bent MJ.

J Neurooncol. 2015 Jan;121(2):365-72. doi: 10.1007/s11060-014-1641-9. Epub 2014 Oct 26.

PMID:
25344884
6.

Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy.

Iwadate Y, Matsutani T, Shinozaki N, Saeki N.

Anticancer Res. 2011 Dec;31(12):4475-9.

PMID:
22199318
7.

Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?

Ramirez C, Bowman C, Maurage CA, Dubois F, Blond S, Porchet N, Escande F.

Neuro Oncol. 2010 May;12(5):490-9. doi: 10.1093/neuonc/nop071. Epub 2010 Feb 14.

9.

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC.

Cancer Res. 2006 Oct 15;66(20):9852-61.

10.

Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.

Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G.

Brain Pathol. 2004 Apr;14(2):121-30.

PMID:
15193024
11.

Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.

Polivka J Jr, Polivka J, Repik T, Rohan V, Hes O, Topolcan O.

Anticancer Res. 2016 Jan;36(1):471-6.

PMID:
26722084
12.

The Effectiveness of Salvage Treatments for Recurrent Lesions of Oligodendrogliomas Previously Treated with Upfront Chemotherapy.

Kuga D, Hata N, Akagi Y, Amemiya T, Sangatsuda Y, Hatae R, Yoshimoto K, Mizoguchi M, Iihara K.

World Neurosurg. 2018 Jun;114:e735-e742. doi: 10.1016/j.wneu.2018.03.069. Epub 2018 Mar 16.

PMID:
29551724
13.

Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.

Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, Wood L, Prayson R, Elson P, Peereboom DM.

J Neurooncol. 2015 Mar;122(1):111-9. doi: 10.1007/s11060-014-1684-y. Epub 2014 Dec 23.

PMID:
25534576
14.

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

Frenel JS, Leux C, Loussouarn D, Le Loupp AG, Leclair F, Aumont M, Mervoyer A, Martin S, Denis MG, Campone M.

J Neurooncol. 2013 Aug;114(1):85-91. doi: 10.1007/s11060-013-1152-0. Epub 2013 May 17.

PMID:
23681562
15.

Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma.

Jiang H, Zhang Z, Ren X, Zeng W, Wang J, Lin S.

J Neurosurg. 2016 Oct;125(4):995-1001. Epub 2016 Jan 15.

PMID:
26771849
16.

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG.

Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30.

PMID:
11020580
17.

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Loeffler M, Pietsch T, von Deimling A; German Glioma Network.

Clin Cancer Res. 2007 Dec 1;13(23):6933-7.

18.

18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.

Cicone F, Carideo L, Scaringi C, Arcella A, Giangaspero F, Scopinaro F, Minniti G.

Ann Nucl Med. 2019 Jan 3. doi: 10.1007/s12149-018-01328-3. [Epub ahead of print]

PMID:
30607877
19.

Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.

Michaud K, de Tayrac M, D'Astous M, Duval C, Paquet C, Samassekou O, Gould PV, Saikali S.

PLoS One. 2016 Dec 28;11(12):e0168728. doi: 10.1371/journal.pone.0168728. eCollection 2016.

20.

IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI.

Lin Y, Xing Z, She D, Yang X, Zheng Y, Xiao Z, Wang X, Cao D.

Neuroradiology. 2017 Jun;59(6):555-562. doi: 10.1007/s00234-017-1839-6. Epub 2017 May 4.

Supplemental Content

Support Center